

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b>  <b>A61K 31/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/53829</b>  <b>(43) International Publication Date:</b> 3 December 1998 (03.12.98)
<b>(21) International Application Number:</b> PCT/EP98/03174  <b>(22) International Filing Date:</b> 22 May 1998 (22.05.98)  <b>(30) Priority Data:</b> 97201586.1 27 May 1997 (27.05.97) EP (34) Countries for which the regional or international application was filed: NL et al.  <b>(71) Applicants (for all designated States except US):</b> AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). SANOFI [FR/FR]; 32/34, rue Marbeuf, F-75374 Paris Cedex 08 (FR).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HERBERT, Jean, Marc [FR/FR]; P10, rue de l'Amandier, F-31170 Tournefeuille (FR). STIEKEMA, Jacobus, Christianus, Johannes [NL/NL]; Herengracht 393, NL-1016 BC Amsterdam (NL).  <b>(74) Agent:</b> HOGENBIRK, Marijke; P.O. Box 20, NL-5340 BH Oss (NL).		<b>(81) Designated States:</b> AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> USE OF OLIGOSACCHARIDE FOR PREVENTING BLOOD CLOTTING IN EXTRACORPOREAL BLOOD CIRCUITS  <b>(57) Abstract</b>  The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrombin III, for the manufacture of a medicament for preventing blood clotting in patients with an extracorporeal blood circuit.		

USE OF OLIGOSACCHARIDE FOR PREVENTING BLOOD  
CLOTTING IN EXTRACORPOREAL BLOOD CIRCUITS

5 The invention relates to the use of a certain oligosaccharide for the manufacture of a medicament for preventing blood clotting in extracorporeal blood circuits. Further the invention relates to a pharmaceutical composition for said use.

10 Blood clotting in extracorporeal blood circuits needs to be prevented. Otherwise, blood coagulation occurs as soon as blood contacts artificial surfaces. As a remedy, usually unfractionated heparin (UFH) or low molecular weight heparins (LMWH) are used as anticoagulants.

15 Both UFH and LMWH have an effect on several stages of the blood coagulation cascade, both inhibiting factor Xa and thrombin (factor IIa). Factor Xa catalyzes the generation of thrombin and subsequently thrombin regulates the last step in the coagulation cascade. The prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel by cross-linking, thereby initiating thrombus formation. UFH and LMWH have thrombolytic properties, i.e. they induce dissolution of the thrombus formed.

20 Contrary to UFH and LMWH, some synthetic oligosaccharides, especially oligosaccharides described in EP 84,999 and US 5,378,829, highly selectively inhibit factor Xa via antithrombin III (ATIII) but do not have any activity on thrombin. However, notwithstanding the absence of any capacity to inhibit thrombin or to promote thrombolysis, it appeared that those oligosaccharides inhibit thrombus formation, e.g. as occurring in extracorporeal blood circuits.


25 Thus, surprisingly, it has now been found that a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrombin III, is useful for preventing blood clotting in patients with an extracorporeal blood circuit.

The use of the oligosaccharide according to this invention results in effective and safe inhibition of blood clotting, e.g. in patients undergoing haemodialysis, without increased bleeding risks.

30


A preferred oligosaccharide for the use according to this invention is the pentasaccharide with the formula methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-( $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho- $\alpha$ -D-

glucopyranosyl)-(1→4)-O-(2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof (i.e. salts with counter-ions like hydrogen or, more preferably, alkali or earth-alkali metal ions, like sodium, calcium, or magnesium), having the structure:




Particularly preferred is its decasodium salt, known by its code name Org 31540 or SR 90107A (described in Chemical Synthesis to Glycosaminoglycans, Supplement to Nature 1991, 350, 30-33).

Other advantageous pentasaccharides are: methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof (especially its dodecasodium salt described in US 5,378,829), having the structure:



and methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof (especially its nonasodium salt also described in US 5,378,829), having the structure



The use in patients with extracorporeal blood circuits according to the invention includes circuits and intravenous infusion lines used for haemodialysis, renal dialysis, haemofiltration, and the like. Preferred extracorporeal circuits are those used in the treatment of haemodialysis patients.

5 The oligosaccharide can be administered at several stages of the treatment. Preferably, but not limited to this route of administration, the oligosaccharide is administered as an intravenous injection to the mammal undergoing treatment. Preferably, the mammal is a human.

Another route of administration of the oligosaccharide is the introduction thereof into a (dialysis) circuit by other means, e.g. by injecting it either gradually or at once into the system upstream of  
10 the dialysis membrane simultaneously with the introduction of the blood into the circuit. Moreover, the lines and/or further equipment of the extracorporeal circuit can be furnished with the oligosaccharide, preferably by way of a coating (but not limited to this). Alternatively, the oligosaccharide may be adsorbed in the materials of parts of the equipment, e.g. in the membranes used for dialysis.

15 For use according to the invention, the oligosaccharide may be administered enterally or parenterally (especially via the subcutaneous or intravenous route) or may be administered via an external source (*vide supra*), and for humans preferably in a dosage of 0,001-10 mg per kg body weight per dialysis. More preferably, the pentasaccharide is administered at doses of between  
20 0.30 mg and 30 mg per patient per dialysis.

The oligosaccharide may be used alone or may be presented as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition for preventing blood clotting in an extracorporeal blood circuit comprising said oligosaccharide together with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents. The term  
25 "acceptable" means being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

Compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, transdermal, transmucosal, local, or rectal administration, and the like, all in unit dosage forms for administration.

30 For oral administration, the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like. For parenteral administration,

the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.

5 Mixed with such pharmaceutically acceptable auxiliaries, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture), the oligosaccharide may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically acceptable liquids the  
10 oligosaccharide can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.

For use as a coating according to the invention, for example pharmaceutically acceptable polymers may be used as a matrix for the oligosaccharide. Also coatings are included, in which the oligosaccharide is chemically (e.g. covalently) linked to the surface without loss of its  
15 activity. Any pharmaceutically acceptable coating may be suitable for this purpose, prepared according to methods conventional in the art.

For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers  
20 with which the oligosaccharides of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotone saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.

25 The pharmaceutical composition according to the invention may also be presented in the form of a veterinary composition, such compositions may be prepared by methods conventional in the art.

The invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material  
30 including instructions for the use of the composition for the use as hereinbefore described.

The invention is further illustrated by the following example. This should not be considered to be limiting in any way.

#### EXAMPLE

5

The pentasaccharide Org 31540 / SR 90107 A, as a representative compound for use according to the present invention, has been subject to a pilot clinical study in 12 patients undergoing chronic intermittent haemodialysis.

10 The study consisted of 2 phases (block A and block B). In block A, 10 mg of Org 31540 / SR 90107 A was administered. Thereafter, in block B, 8, 6, and 4 mg of Org 31540 / SR 90107 A were used.

15 Medication was given as an intravenous bolus predialysis for 1 dialysis each week. Efficacy was assessed by determining patency of the dialyzer, buffer and bubble chamber, every hour during dialysis by visual examination and by blood sampling of specific coagulation, hematologic and biochemical parameters. Anti-Xa plasma samples, to determine pharmacokinetics, were taken every hour during dialysis and 1 hour after dialysis and daily for 3 days post-dialysis. Safety was assessed by evaluating major and minor bleeding complications each dialysis.

20 Results: All patients have completed the study. Dialysis could be performed without total clotting of the extracorporeal circuit in all patients for all study dialyses. Only in one patient a clot in the buffer chamber made dialysis impossible half an hour before the end of the last dialysis. No minor or major bleedings were recorded.

25 Conclusion: The pentasaccharide Org 31540 / SR 90107 A is a safe (no increased haemorrhagic risks) and effective (at several doses) anticoagulant to prevent clotting in the extracorporeal blood circuit in haemodialysis patients.

CLAIMS

1. A use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrombin III, for the manufacture of a medicament for preventing blood clotting in patients with an extracorporeal blood circuit.
2. The use according to claim 1, wherein the oligosaccharide is the pentasaccharide methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-( $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2-O-sulpho- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2-deoxy-2-sulphoamino-6-O-sulpho- $\alpha$ -D-glucopyranoside or a pharmaceutically acceptable salt thereof.
3. The use of claim 2, wherein the pentasaccharide is in the form of its decasodium salt.
4. The use according to any one of claims 1-3, wherein the extracorporeal blood circuit is of haemodialysis patients.
5. The use according to any one of claims 1-4, wherein the medicament is suitable for intravenous administration.
6. The use according to any one of claims 1-4, wherein the medicament is adapted for use as an anticoagulant coating.
7. The use according to any one of claims 1-6, wherein the medicament is in a unit dosage form.
8. A method of preventing blood clotting in a mammal undergoing a treatment in which an extracorporeal blood circuit is used, comprising the administration to said mammal of a therapeutically effective amount of the oligosaccharide as defined in claim 1 or 2 or a pharmaceutically acceptable salt thereof.

9. A method of preventing blood clotting in an extracorporeal blood circuit, comprising furnishing components of the circuit with a therapeutically effective amount of the oligosaccharide as defined in claim 1 or 2, or a pharmaceutically acceptable salt thereof.
- 5 10. A pharmaceutical composition adapted for preventing blood clotting in an extracorporeal blood circuit comprising the oligosaccharide as defined in claim 1 or 2, or a pharmaceutically acceptable salt thereof, together with pharmaceutically acceptable auxiliaries.



# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/EP 98/03174

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 084 999 A (CHOAY) 3 August 1983 cited in the application see page 6	10
Y	see page 32, line 22 - line 34 see page 37, line 1 - line 11 see page 38 - page 41 see example 9 see figures 10,11 --- -/--	1-5,8,9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 September 1998

Date of mailing of the international search report

22/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

## INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/EP 98/03174

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MESSMORE: "Clinical efficacy of heparin fractions : issues and answers" CRIT. REV. CLIN. LAB. SCI., vol. 23, no. 2, 1986, pages 77-94, XP002046070 see page 79, paragraph 4 see page 80, paragraph 3 * page 84 : hemodialysis * see page 85, paragraph 1-3 * page 88 : X. Hemodialysis * ---	1-5,8,9
X	LORMEAU: "The effect of the synthetic pentasaccharide SR90107/ORG31540 on thrombin generation Ex Vivo is uniquely due to AT-III-mediated neutralization of factor Xa" THROMB. HAEMOST., vol. 74, no. 6, December 1995, pages 1474-1477, XP002046071 see the whole document	10
Y	---	1-4,8,9
X	CADROY: "Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates" THROMB. HAEMOST., vol. 70, no. 4, 18 October 1993, pages 631-635, XP002046072 see the whole document	10
Y	---	1-4,8,9
X	VOGEL: "Pentasaccharide and Orgaran(R) arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt" THROMB. HAEMOST., vol. 69, no. 1, 11 January 1993, pages 29-34, XP002046073 see the whole document	10
Y	---	1-4,8,9
X	BERNAT: "The synthetic pentasaccharide SR90107A/ORG31540 enhances tissue-type plasminogen-induced thrombolysis in rabbits." FIBRINOLYSIS, vol. 10, no. 3, 1996, pages 151-157, XP002046074 see the whole document	10
A	---	1-3,5,8,9
	---	
	-/--	

# INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/EP 98/03174

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FREEDMAN: "Pharmacodynamics, clinical indications, and adverse effects of heparin"  J. CLIN. PHARMACOL.,  vol. 32, no. 7, 1992, pages 584-591,  XP002046075  * whole document especially page 591 right column *</p>	1-5,8,9
X	<p>SCHIELE: "Initial experience of sulphated pentasaccharide, a pure factor Xa inhibitor, in coronary angioplasty"  CIRCULATION,  vol. 94, no. 8suppl., 1996, page I742  XP002046076  * abstract nr 4340 *</p>	10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03174

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 84999 A	03-08-1983	FR 2519987 A	22-07-1983
		FR 2520744 A	05-08-1983
		FR 2521566 A	19-08-1983
		FR 2527614 A	02-12-1983
		FR 2528853 A	23-12-1983
		FR 2528854 A	23-12-1983
		FR 2529557 A	06-01-1984
		FR 2531436 A	10-02-1984
		FR 2533219 A	23-03-1984
		FR 2533220 A	23-03-1984
		FR 2535306 A	04-05-1984
		AU 563351 B	09-07-1987
		AU 1039783 A	21-07-1983
		CA 1247608 A	27-12-1988
		CA 1265132 A	30-01-1990
		DE 3376265 A	19-05-1988
		DK 14383 A	16-07-1983
		EP 0082793 A	29-06-1983
		JP 1849958 C	21-06-1994
		JP 58170797 A	07-10-1983
		JP 2510454 B	26-06-1996
		JP 5331182 A	14-12-1993
		US 4818816 A	04-04-1989
		US 4987223 A	22-01-1991
		US 4801583 A	31-01-1989
		BE 898096 A	15-02-1984